Anti-HIV group I introns and uses thereof in treating HIV infections



Described is a unique class of antiviral molecule that can be applied to control and eliminate HIV infection in patients using myeloablation therapies and replenishment with transformed bone marrow stem cells programmed to express the antiviral molecule. These anti-viral molecules target the HIV genome in a highly conserved domain, and when expressed in cells prior to infection will cause the cell to die upon infection with HIV. Cell death insures no proliferation of new virus. Reconstituting the immune system with cells expressing these antivirals prevents re-establishment of HIV infection from reservoirs in the re-established lymphocyte and macrophage populations. Over time, reservoirs will be depleted entirely, effectively eliminating the virus. In effect, this new type of antiviral can be used to cure HIV infections.


Attribute NameValues
  • Anti-HIV group I introns and uses thereof in treating HIV infections

Patent Number
  • US 9707257 B2

  • Malcolm J. Fraser

Inventor From Local Institution
  • Malcolm J. Fraser

Other Application
  • 13/096,626

Prior Publication Date
  • 2012-11-01

Prior Publication Number
  • US 20120276071 A1

  • 24

Cooperative Patent Classification codes
  • A61K 35/545 (20130101); C12N 15/1132 (20130101); C12N 2310/124 (20130101); C12N 2310/3519 (20130101)

International Patent Classification codes
  • C12N 15/113 (20100101); C12N 15/12 (20060101); C12N 15/11 (20060101); A61K 35/545 (20150101)

  • English

Date Issued
  • 2017-07-18

  • U.S. Patent and Trademark Office

  • University of Notre Dame du Lac

Record Visibility Public
Content License
  • All rights reserved

Departments and Units
Member of


Collections Featuring this Patent
Notre Dame Patents


Please Note: You may encounter a delay before a download begins. Large or infrequently accessed files can take several minutes to retrieve from our archival storage system.